- Home
- DMAC vs OTLY Comparison
DMAC vs OTLY Comparison
Compare DMAC & OTLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- OTLY
- Stock Information
- Founded
- DMAC 2000
- OTLY 1994
- Country
- DMAC United States
- OTLY Sweden
- Employees
- DMAC N/A
- OTLY N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- OTLY Packaged Foods
- Sector
- DMAC Health Care
- OTLY Consumer Staples
- Exchange
- DMAC Nasdaq
- OTLY Nasdaq
- Market Cap
- DMAC 260.0M
- OTLY 303.5M
- IPO Year
- DMAC N/A
- OTLY 2021
- Fundamental
- Price
- DMAC $4.76
- OTLY $14.40
- Analyst Decision
- DMAC Strong Buy
- OTLY Buy
- Analyst Count
- DMAC 4
- OTLY 5
- Target Price
- DMAC $10.75
- OTLY $19.60
- AVG Volume (30 Days)
- DMAC 353.4K
- OTLY 142.3K
- Earning Date
- DMAC 08-06-2025
- OTLY 07-23-2025
- Dividend Yield
- DMAC N/A
- OTLY N/A
- EPS Growth
- DMAC N/A
- OTLY N/A
- EPS
- DMAC N/A
- OTLY N/A
- Revenue
- DMAC N/A
- OTLY $828,200,000.00
- Revenue This Year
- DMAC N/A
- OTLY $4.31
- Revenue Next Year
- DMAC N/A
- OTLY $5.01
- P/E Ratio
- DMAC N/A
- OTLY N/A
- Revenue Growth
- DMAC N/A
- OTLY 4.43
- 52 Week Low
- DMAC $3.19
- OTLY $6.00
- 52 Week High
- DMAC $6.82
- OTLY $21.20
- Technical
- Relative Strength Index (RSI)
- DMAC 64.04
- OTLY 64.93
- Support Level
- DMAC $4.81
- OTLY $13.97
- Resistance Level
- DMAC $5.60
- OTLY $15.53
- Average True Range (ATR)
- DMAC 0.45
- OTLY 0.78
- MACD
- DMAC 0.11
- OTLY 0.04
- Stochastic Oscillator
- DMAC 67.90
- OTLY 75.46
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.